Clinical Trials – Surufatinib for Neuroendocrine Cancer

Clinical Trials – Surufatinib for Neuroendocrine Cancer

Clinical Trials
Share on facebook Facebook Share on twitter Twitter Share on pinterest Pinterest Share on whatsapp WhatsApp Share on email Email An extremely interesting drug in the pipeline which has been featured at ENETS, NANETS, ESMO and ASCO. Chi-Med will submit a New Drug Application (NDA) to the US FDA for them to consider approval.  It is anticipated the NDA will arrive in FDA by the end of this year.  Additionally, Chi-Med has received advice from the European Medicines Agency's (EMA) to submit a marketing authorization application (MAA).  Given that no filing issues were identified, the MAA submission is planned for 2021, following submission for the U.S. FDA NDA. The story follows PRESS RELEASE: LONDON, June 01, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (Chi-Med) today announces that it has…
Read More